Clinician's guide to the management of azoospermia induced by exogenous testosterone or anabolic-androgenic steroids.
Level 5 - mechanism / opinion, no new human data
Narrative review and clinical guide without systematic search methodology or new empirical data
PubMed 39820213 · doi:10.4103/aja2024104
What was done
This paper is a narrative clinical review describing the pathophysiological mechanisms of hypothalamic-pituitary-gonadal (HPG) axis suppression caused by exogenous testosterone and anabolic-androgenic steroids, along with proposed treatment and prevention protocols for resulting azoospermia.
What was found
The abstract reports no numerical values, effect sizes, or statistical findings. It outlines qualitative clinical strategies: cessation of exogenous testosterone and observation for spontaneous recovery (especially with short-duration use), hormonal rescue using human chorionic gonadotropin (hCG), follicle-stimulating hormone (FSH), and selective estrogen receptor modulators (SERMs like clomiphene citrate) alone or in combination, and prevention via short-acting formulations or concomitant low-dose hCG.
Why it matters
With rising global use of testosterone replacement therapy and anabolic steroids, clinicians require structured strategies to manage drug-induced male infertility and restore spermatogenesis.
Limits
This is an unstructured narrative review rather than a systematic review or randomized trial. The abstract provides no quantitative success rates or sample size metrics, and the authors emphasize a significant lack of well-structured, controlled, and long-term studies supporting these management strategies.